Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Corporate Profile for Yamanouchi Pharma Technologies, dated March 3, 2000.


Business Editors

--(BUSINESS WIRE)

The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services.

Published Date:   March 3, 2000

Company Name:     Yamanouchi Pharma Technologies, Inc.

Address:          1050 Arastradero Road
                  Palo Alto, CA 94304

Main Telephone
 Number:          650/849-8505

Internet Home
 Page Address
  (URL)           www.ypharma.com

Chief Executive
 Officer:         Dan L. Green

Chief Financial
 Officer:         Nevin N. Andersen

Investor Relations
 Business number: 877/663-3643

Public Relations
 Contact:         Grace N. Hill
 Business number: 650/849-8595
 E-mail address:  ghill@ypharma.com

Industry:         Pharmaceutical


Company Description: Yamanouchi Pharma Pharma may be an abbreviation for:
  • Pharmaceutical company
  • Pharmaceutical drug
  • Pharmacology
  • Pharmaceutical Research and Manufacturers of America (PhRMA)
  • Pharma (record label)
 Technologies, Inc. is a drug delivery company charged with the worldwide introduction and commercialization of specialized spe·cial·ize  
v. spe·cial·ized, spe·cial·iz·ing, spe·cial·iz·es

v.intr.
1. To pursue a special activity, occupation, or field of study.

2.
 drug delivery technologies, partnering with multinational pharmaceutical companies.

The company has been successful in establishing its business with its premier technologies, which include WOWTAB(R), plus the controlled release system, OCAS OCAS
abbr.
Organization of Central American States

OCAS n abbr (= Organization of Central American States) → ODECA f

OCAS n abbr (=
(TM) and the colon-targeted release system, CODES(TM).

Located in the Stanford Research Park Stanford Research Park is a technology park located in Palo Alto, California on land owned by Stanford University. Built in 1951, as Stanford Industrial Park, it claims to be the world's first technology-focused office park.  in Palo Alto Palo Alto, city, California
Palo Alto (păl`ō ăl`tō), city (1990 pop. 55,900), Santa Clara co., W Calif.; inc. 1894. Although primarily residential, Palo Alto has aerospace, electronics, and advanced research industries.
, Calif., Yamanouchi Pharma Technologies, Inc. is a wholly-owned subsidiary of Yamanouchi Pharmaceutical Co., Ltd. Founded in 1923, Yamanouchi Pharmaceutical Co., Ltd. has established an international reputation as a research-oriented company and as a leader in the pharmaceuticals industry. With operations worldwide, Yamanouchi ranks third in sales in the Japanese Japanese (jăp'ənēz`), language of uncertain origin that is spoken by more than 125 million people, most of whom live in Japan. There are also many speakers of Japanese in the Ryukyu Islands, Korea, Taiwan, parts of the United States, and  pharmaceutical market.
COPYRIGHT 2000 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Mar 3, 2000
Words:229
Previous Article:Corporate Profile for UNICO Inc., dated March 3, 2000.
Next Article:UCBH Holdings, Inc. Declares $0.05 Dividend for the First Quarter of 2000.



Related Articles
PHARMACEUTICAL COMPANIES USE GENOMIC INFORMATION IN R&D.
Astellas Establishes Venture Management Company in US.
Astellas and Toyama Chemical Announce Basic Licensing Agreement on Domestic Marketing and Joint Development of Quinolone Antibiotic T-3811.
Astellas Establishes New Subsidiary 'Astellas Pharma Chemicals Co., Ltd.'.
Ilypsa and Astellas Enter a Licensing Agreement on ILY101 for Treatment of Hyperphosphatemia in Japan.
Astellas Discontinues Development of Immunosuppressant FK778.
ASTELLAS' SCREENING TRIGGERS MILESTONE PAYMENT TO METABOLEX.
Dainippon Sumitomo Pharma 2006 Annual Report to Shareholders, 'True Quality, Our New Beginning'.
Astellas Transfers Three European Plants to Temmler Group, German Pharmaceutical Company.
Astellas and Pfizer Reached Settlement on Declaratory Judgment Action Relating to Lipitor Agreement.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles